6.5
Hemmung der Cdk-Aktivität
View the full transcript and gain access to JoVE Core videos
Q1: How does cyclin degradation regulate Cdk activity during the cell cycle?
Cdks are only active when bound to cyclin, so cyclin degradation directly inactivates them and prevents progression to the next cell cycle stage. Cyclin levels fluctuate throughout the cell cycle, controlling when Cdks can function. This mechanism ensures cells transition through phases in an orderly, controlled manner.
Q2: What role does the Wee1 kinase play in inhibiting Cdk activity?
Wee1 phosphorylates the active site of Cdk, directly inhibiting the activity of the cyclin-Cdk complex. This phosphorylation-based inhibition represents a key regulatory mechanism that prevents uncontrolled cell cycle progression. Wee1 activity helps ensure cells complete necessary processes before advancing to subsequent phases.
Q3: How do Cdk inhibitor proteins like p16 and p21 stop cell cycle progression?
Cdk inhibitors such as p16, p21, and p27 bind to cyclin-Cdk complexes and induce inhibitory conformational changes. For example, p16 binding causes structural rearrangement that detaches cyclin from Cdk, inactivating it. p21 is activated by the tumor suppressor p53 in response to DNA damage, arresting cells in G1 phase to allow time for DNA repair.
Q4: What happens when DNA damage occurs during the G1 phase of the cell cycle?
DNA damage in G1 triggers the tumor suppressor protein p53 to activate p21, which binds and inhibits G1/S-Cdk and S-Cdk complexes. This arrests the cell in G1 phase, providing sufficient time for DNA repair mechanisms to fix the damage before the cell proceeds to S phase and DNA replication.
Q5: How do clinical Cdk4/6 inhibitors like palbociclib work to treat cancer?
Cdk4/6 inhibitors such as palbociclib, abemaciclib, and ribociclib bind to the ATP pocket of Cdk4 and Cdk6, inactivating Cyclin D-Cdk4/6 complexes. This leads to reactivation of the tumor suppressor Rb protein and subsequent cell cycle arrest. In some cases, this arrest triggers apoptosis in tumor cells, providing an anticancer effect.
Q6: Why is Cdk activity regulation critical for preventing cancer development?
Without proper regulatory mechanisms, Cdk activity goes unchecked, leading to abnormal cell proliferation and cancer. Normal cells regulate Cdk through cyclin degradation, inhibitory phosphorylation, and Cdk inhibitor binding. Mutations that prevent these regulatory mechanisms result in Cdk-mediated tumorigenesis, making Cdk inhibitors extensively studied as anticancer agents.
Q7: How does p27 regulate cell cycle progression when cellular resources are limited?
When a cell lacks necessary resources for DNA replication, p27 binds to G1/S-Cdk and S-Cdk complexes, inhibiting their enzyme activity and halting cell cycle progression. Once favorable conditions for cell cycle progression are met, p27 is degraded, restoring Cdk activity and allowing the cell to advance through the cycle.